Cambrex’s Post

Did you miss our webinar last month? You can watch the recording and hear from our experts as they discuss innovations in liquid-phase peptide synthesis, peptide crystallization, method development for peptide impurity analysis and more.

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐍𝐞𝐰 𝐁𝐥𝐨𝐠 Peptide Design and Synthesis under GMP Conditions If you are investigating potential peptide therapeutics, you will need GMP grade peptides for your clinical trials. However, do you know what it means to produce peptides for your clinical trials under GMP conditions? Read the new Blog of Intavis via link in the comment. #Peptides #GMP

With so much interest in oral GLP-1s across the industry, now is the perfect time to dive into the biopharmaceutical considerations behind their development 🚀 I'm excited to share a link to our upcoming webinar, where we'll explore the key factors shaping this growing area of research. Don't miss this opportunity to hear from the experts and stay ahead in this rapidly evolving field! #QuotientSciences #Webinar #GLP1 #OralTherapeutics #DrugDevelopment

🚨 NEWS 🚨 @US_FDA accepts supplemental biologics license application for glofitamab-gxbm in combination with gemcitabine and oxaliplatin for R/R DLBCL after ≥1 prior lines of systemic therapy. Read more here 👉 https://loom.ly/qgALDQc #lymsm #lymphoma #MedNews

In this on-demand webinar, explore strategies to master GLP-1 production, along with proven and robust technologies tailored for peptide therapeutics with a focus on GLP-1. Watch now: https://sar.to/ym8ad #SimplifyingProgress #InThisTogether #GLP1

Oncogenic Therapeutics saw a 53.85% increase in its stock price on the first day of its KOSDAQ listing, with its flagship drug Zaqubo driving growth projections. #OncogenicTherapeutics #KOSDAQ #Zaqubo #Stock #Market https://lnkd.in/gxtAzsYa

Alastair Hay and Daniel DeOliveira, Ph.D., PMP are at the Peptide Therapeutics Symposium in La Jolla this week, ready to discuss your outsourcing requirements for peptide development and manufacture. Stop by and say hello to our team to learn more. #peptidedevelopment #drugdevelopment #peptides

Dive deep into the world of Phosphodiesterase (PDE) Inhibitors! 🧬 DelveInsight's latest report unveils the cutting-edge developments in PDE inhibitor drugs. With over 40 key companies driving innovation, the global pipeline boasts 40+ promising therapies. 🌐 From clinical trials to FDA approvals, this comprehensive analysis sheds light on the mechanisms, routes of administration, and emerging trends shaping the market. Discover the powerhouses behind PDE inhibitor therapies like Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), Chiesi Group, Imara Inc, Verona Pharma, Eisai Co., Ltd., vTv Therapeutics LLC, Tetra Therapeutics, Palobiofarma S.L., and others. Brace for groundbreaking treatments such as ARQ-151 and Ensifentrine, poised to revolutionize PDE inhibitor therapy worldwide. Ready to explore the future of healthcare? Request your free sample report now:  https://lnkd.in/gjBnzW2a #PhosphodiesteraseInhibitors #HealthcareInnovation #ClinicalTrials #FutureOfMedicine #healthcare #biotechnology #lifesciences #pharmaceuticalindustry #pharmaceutical #marketresearch #marketforecast #markettrends #consulting #healthcareconsulting #consultingservices #marketforecast

$TNYA - Pin risk slips as more Tenaya Therapeutics call traders are getting in: As of the 22nd of September, Tenaya Therapeutics has the Risk Adjusted Performance of (0.06), variance of 29.98, and Coefficient Of Variation of (1,220). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tenaya Therapeutics, as well as the relationship between them. https://lnkd.in/g5Zb58Y5

AbbVie to acquire Nimble Therapeutics in $200m deal The deal will provide AbbVie access to Nimble's proprietary peptide synthesis platform, which facilitates the discovery and optimisation of oral peptide therapeutics. Read more: https://lnkd.in/eXbg4W8f #pharmaindustry #pharmaceuticalindustry #peptidesynthesis #peptidethrapeutics #abbvie #nimbletherapeutics #worldpharma